Display options
Cite
Herrington DM, Nanjee N, Achuff SC, et al. Dehydroepiandrosterone and cardiac allograft vasculopathy. J Heart Lung Transplant. 1996;15(1):88-93
Herrington, D. M., Nanjee, N., Achuff, S. C., Cameron, D. E., Dobbs, B., & Baughman, K. L. (1996). Dehydroepiandrosterone and cardiac allograft vasculopathy. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 15(1), 88-93.
Herrington, D M, et al. "Dehydroepiandrosterone and cardiac allograft vasculopathy." The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation vol. 15,1 (1996): 88-93.
Herrington DM, Nanjee N, Achuff SC, Cameron DE, Dobbs B, Baughman KL. Dehydroepiandrosterone and cardiac allograft vasculopathy. J Heart Lung Transplant. 1996 Jan;15(1):88-93. PMID: 8820087.
Copy Download .nbib Format: NLM
Share it on

J Heart Lung Transplant. 1996 Jan;15(1):88-93.

Dehydroepiandrosterone and cardiac allograft vasculopathy.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

D M Herrington, N Nanjee, S C Achuff, D E Cameron, B Dobbs, K L Baughman

Affiliations

  1. Division of Cardiology, The Bowman Gray School of Medicine, Winston-Salem, NC 27157-1045, USA.

PMID: 8820087

Abstract

BACKGROUND: Tissue culture, animal model, and epidemiologic studies suggest that dehydroepiandrosterone may inhibit atherosclerosis through its potent antiproliferative effects. Because cardiac allograft vasculopathy is predominantly a proliferative abnormality of intimal and medial smooth muscle cells, plasma levels of dehydroepiandrosterone may play an important role in the development of this disease.

METHODS: Sixty-one cardiac allograft recipients who survived for 1 year or more and had at least one annual follow-up cardiac catheterization were included in the study. Plasma levels of dehydroepiandrosterone, dehydroepiandrosterone sulfate, and free dehydroepiandrosterone (dehydroepiandrosterone not bound to sex hormone-binding globulin) were measured in all 61 subjects and compared with the presence or absence of cardiac allograft vasculopathy as defined by angiography.

RESULTS: Plasma levels of total and free dehydroepiandrosterone were lower in subjects in whom cardiac allograft vasculopathy developed (p = 0.005 and 0.003, respectively). Furthermore, the time to development of cardiac allograft vasculopathy was shorter in subjects with low levels of total and free dehydroepiandrosterone (p = 0.062 and 0.046, respectively). This relationship was maintained after adjusting for age, gender, cholesterol, prednisone use, and blood pressure.

CONCLUSIONS: Low plasma levels of dehydroepiandrosterone may facilitate and high levels may retard the development of cardiac allograft vasculopathy.

Substances

MeSH terms

Publication Types